FIELD: organic chemistry.
SUBSTANCE: invention relates to chemistry of organic compounds, pharmacology and medicine, and concerns novel antiviral peptides.
EFFECT: disclosed peptides are characterized by high antiviral activity and are promising for use in the therapy of infectious diseases in a subject caused by a viral infection, including diseases caused by SARS-CoV-2, for example, simple infection (such as fever, cough and/or sore throat), pneumonia, acute or severe respiratory infection, hypoxic respiratory failure, acute respiratory distress syndrome, sepsis or septic shock, particularly COVID-19.
9 cl, 2 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-SARS-COV-2 VIRAL AGENT ANTIPROVIR | 2020 |
|
RU2738885C1 |
| THERAPEUTIC AGENT AGAINST CORONAVIRUS INCLUDING AN ELAEOCARPUS SYLVESTRIS EXTRACT | 2021 |
|
RU2780346C1 |
| PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRAL DISEASES | 2021 |
|
RU2780252C1 |
| METHOD FOR THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2775966C1 |
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
| COMPOSITIONS AND METHODS FOR TREATING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) | 2004 |
|
RU2411042C2 |
| USE OF 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES IN ANTIVIRAL THERAPY | 2021 |
|
RU2820287C1 |
| METHODS FOR TREATING INFECTIOUS DISEASES CAUSED BY CORONAVIRUS | 2021 |
|
RU2772701C1 |
| METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
| USE OF DISULFIRAM IN CORONAVIRUS RESISTANCE | 2021 |
|
RU2829731C1 |
